JNJ

192.81

+0.35%↑

ABT

127.86

+0.06%↑

MDT

95.84

-0.02%↓

VEEV

289.4

-0.16%↓

145.98

+0.05%↑

JNJ

192.81

+0.35%↑

ABT

127.86

+0.06%↑

MDT

95.84

-0.02%↓

VEEV

289.4

-0.16%↓

145.98

+0.05%↑

JNJ

192.81

+0.35%↑

ABT

127.86

+0.06%↑

MDT

95.84

-0.02%↓

VEEV

289.4

-0.16%↓

145.98

+0.05%↑

JNJ

192.81

+0.35%↑

ABT

127.86

+0.06%↑

MDT

95.84

-0.02%↓

VEEV

289.4

-0.16%↓

145.98

+0.05%↑

JNJ

192.81

+0.35%↑

ABT

127.86

+0.06%↑

MDT

95.84

-0.02%↓

VEEV

289.4

-0.16%↓

145.98

+0.05%↑

Kodu・Aktsiate loetelu・Arbutus Biopharma Corp

Arbutus Biopharma Corp

Suletud

4.42 -1.12

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

4.36

Max

4.47

Põhinäitajad
By Trading Economics
Sissetulek	27M 2.5M
Müük	9M 11M
Kasumimarginaal	23.494
Töötajad	44
EBITDA	27M 2.6M

Turustatistika
By TradingEconomics
Turukapital	233M 872M
Eelmine avamishind	5.54
Eelmine sulgemishind	4.42

Tehniline skoor

By Trading Central

Kindlus

Weak Bearish Evidence

3.255 / 3.365 Toetus ja vastupanu

Arbutus Biopharma Corp Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

22. okt 2025, 22:47 UTC

Omandamised, ülevõtmised, äriostud

Woodside Energy Signs Up Williams as Investor in Louisiana LNG Project -- Update

22. okt 2025, 22:13 UTC

Omandamised, ülevõtmised, äriostud

Woodside Energy Signs Up Williams as Investor in Louisiana LNG Project

22. okt 2025, 21:20 UTC

Tulu

Correction to IBM 3Q Sales Jump Article

22. okt 2025, 20:57 UTC

Tulu

SAP Posts Higher 3Q Revenue, Operating Profit

22. okt 2025, 23:46 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

22. okt 2025, 23:46 UTC

Market Talk

Nikkei May Decline Amid U.S.-China Trade Tensions -- Market Talk

22. okt 2025, 23:41 UTC

Market Talk

Gold Extends Pullback on Likely Profit-Taking -- Market Talk

22. okt 2025, 23:38 UTC

Market Talk

Gold Extends Pullback on Likely Profit-Taking -- Market Talk

22. okt 2025, 23:15 UTC

Tulu

Tesla Profit Plunges Despite Third-Quarter Rush to Buy EVs -- 4th Update

22. okt 2025, 22:28 UTC

Market Talk

Alcoa Cautions About Spending More on U.S. Smelters -- Market Talk

22. okt 2025, 22:02 UTC

Tulu

Tesla Profit Plunges Despite Third-Quarter Rush to Buy EVs -- 3rd Update

22. okt 2025, 21:59 UTC

Omandamised, ülevõtmised, äriostud

Williams Cos.: Entered Into 1.5 Mtpa LNG Offtake Obligation >WMB

22. okt 2025, 21:58 UTC

Omandamised, ülevõtmised, äriostud

Williams Cos. to Buy 10% Interest in Louisiana LNG LLC >WMB

22. okt 2025, 21:57 UTC

Omandamised, ülevõtmised, äriostud

Williams Cos. to Buy 80% Ownership In, Become Operator of Driftwood Pipeline >WMB

22. okt 2025, 21:56 UTC

Omandamised, ülevõtmised, äriostud

Williams Cos.: Strategic Partnership Entered With Woodside Energy to Invest in Louisiana LNG Project >WMB

22. okt 2025, 21:47 UTC

Omandamised, ülevõtmised, äriostud

Woodside: Williams to Assume LNG Offtake Obligations for 10% of Produced Volumes

22. okt 2025, 21:47 UTC

Tulu

SAP Stock Drops After Earnings. Cloud Revenue Fell Short. -- Barrons.com

22. okt 2025, 21:47 UTC

Omandamised, ülevõtmised, äriostud

Woodside: Williams to Contribute Its Share of Capex for LNG Facility, Pipeline

22. okt 2025, 21:46 UTC

Omandamised, ülevõtmised, äriostud

Woodside Energy Says Williams Deals Worth US$378 Million Including Capital Reimbursement

22. okt 2025, 21:45 UTC

Omandamised, ülevõtmised, äriostud

Woodside Energy to Sell 80% Interest in Driftwood Pipeline Co. to Williams

22. okt 2025, 21:45 UTC

Omandamised, ülevõtmised, äriostud

Woodside Energy to Sell 10% Interest in Louisiana LNG Holding Co. to Williams

22. okt 2025, 21:28 UTC

Market Talk

Tulu

Correction to Alcoa Tariff Market Talk

22. okt 2025, 21:25 UTC

Tulu

Wall Street Wonders if Grail's Cancer Test Results Are a True Positive -- Barrons.com

22. okt 2025, 21:17 UTC

Tulu

Tesla Profit Plunges Despite Third-Quarter Rush to Buy EVs -- 2nd Update

22. okt 2025, 21:09 UTC

Market Talk

Tulu

Alcoa Says Delivery Fee Covering Tariff Costs -- Market Talk

22. okt 2025, 21:00 UTC

Market Talk

ESG Roundup: Market Talk

22. okt 2025, 20:59 UTC

Tulu

SAP Stock Drops After Earnings. Cloud Revenue Fell Short. -- Barrons.com

22. okt 2025, 20:51 UTC

Tulu

SAP Reports Mixed Earnings. The Stock is Down. -- Barrons.com

22. okt 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

22. okt 2025, 20:44 UTC

Tulu

Kaiser Aluminum: For the Full Yr 2025, Now Expects Conversion Rev to Be Flat to Up 5% Yr-Over-Yr and Raises Adjusted EBITDA Outlook to Improve 20% to 25% Yr-Over-Yr >KALU

Võrdlus sarnastega

Hinnamuutus

Arbutus Biopharma Corp Prognoos

Hinnangu Konsensus

By TipRanks

0 ratings

Osta

Hoia

Müü

Põhineb 0 analüütiku instrumendi Arbutus Biopharma Corp aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

3.255 / 3.365Toetus ja vastupanu

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Arbutus Biopharma Corp

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.